QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)

Concert Pharmaceuticals - CNCE Stock Forecast, Price & News

$6.40
-0.31 (-4.62%)
(As of 10/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.32
$6.72
50-Day Range
$5.07
$7.20
52-Week Range
$2.57
$7.37
Volume
334,399 shs
Average Volume
461,241 shs
Market Capitalization
$232.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.60

Concert Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
169.5% Upside
$17.25 Price Target
Short Interest
Healthy
3.41% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.72) to ($1.82) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.50 out of 5 stars

Medical Sector

187th out of 1,072 stocks

Pharmaceutical Preparations Industry

78th out of 534 stocks

CNCE stock logo

About Concert Pharmaceuticals (NASDAQ:CNCE) Stock

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Receive CNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNCE Stock News Headlines

Recap: Concert Pharma Q2 Earnings
Concert Pharmaceuticals: A Balanced Risk/Reward
See More Headlines
Receive CNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNCE Company Calendar

Last Earnings
8/04/2022
Today
10/05/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CNCE
Employees
64
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.25
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+143.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-80,050,000.00
Pretax Margin
-21,504.86%

Debt

Sales & Book Value

Annual Sales
$32.58 million
Book Value
$3.24 per share

Miscellaneous

Free Float
32,213,000
Market Cap
$232.51 million
Optionable
Optionable
Beta
0.58

Key Executives

  • Mr. Richard H. Aldrich M.B.A. (Age 68)
    Mba, Co-Founder & Independent Chairman
    Comp: $80k
  • Dr. Roger D. Tung Ph.D. (Age 62)
    Co-Founder, CEO, Pres & Exec. Director
    Comp: $979.29k
  • Mr. Marc A. BeckerMr. Marc A. Becker (Age 50)
    Chief Financial Officer
    Comp: $677.05k
  • Dr. James V. Cassella Ph.D. (Age 67)
    Chief Devel. Officer
    Comp: $738.48k
  • Ms. Nancy StuartMs. Nancy Stuart (Age 64)
    Chief Operating Officer
  • Ms. Justine E. Koenigsberg
    Sr. VP of Corp. Communications & Investor Relations
  • Mr. Jeffrey A. MunsieMr. Jeffrey A. Munsie (Age 45)
    Chief Legal Officer & Corp. Sec.
  • Dr. Nabil Uddin Pharm.D.
    VP of Corp. Devel.
  • Ms. Christine Boisclair
    Sr. VP of Regulatory Affairs & Quality Assurance













CNCE Stock - Frequently Asked Questions

Should I buy or sell Concert Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CNCE shares.
View CNCE analyst ratings
or view top-rated stocks.

What is Concert Pharmaceuticals' stock price forecast for 2022?

4 analysts have issued 12-month price objectives for Concert Pharmaceuticals' shares. Their CNCE share price forecasts range from $10.00 to $25.00. On average, they expect the company's stock price to reach $17.25 in the next year. This suggests a possible upside of 171.2% from the stock's current price.
View analysts price targets for CNCE
or view top-rated stocks among Wall Street analysts.

How have CNCE shares performed in 2022?

Concert Pharmaceuticals' stock was trading at $3.15 at the start of the year. Since then, CNCE shares have increased by 101.9% and is now trading at $6.36.
View the best growth stocks for 2022 here
.

When is Concert Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our CNCE earnings forecast
.

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) released its quarterly earnings results on Thursday, August, 4th. The biotechnology company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.31. The biotechnology company earned $0.02 million during the quarter, compared to analysts' expectations of $0.33 million.

What is Roger Tung's approval rating as Concert Pharmaceuticals' CEO?

1 employees have rated Concert Pharmaceuticals Chief Executive Officer Roger Tung on Glassdoor.com. Roger Tung has an approval rating of 100% among the company's employees. This puts Roger Tung in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Concert Pharmaceuticals own?
What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

How do I buy shares of Concert Pharmaceuticals?

Shares of CNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Concert Pharmaceuticals' stock price today?

One share of CNCE stock can currently be purchased for approximately $6.36.

How much money does Concert Pharmaceuticals make?

Concert Pharmaceuticals (NASDAQ:CNCE) has a market capitalization of $231.06 million and generates $32.58 million in revenue each year. The biotechnology company earns $-80,050,000.00 in net income (profit) each year or ($3.41) on an earnings per share basis.

How can I contact Concert Pharmaceuticals?

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The official website for the company is www.concertpharma.com. The biotechnology company can be reached via phone at (781) 860-0045, via email at ir@concertpharma.com, or via fax at 302-636-5454.

This page (NASDAQ:CNCE) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.